| Novartis Pharma Schweiz AG - Optaflu, Injektionssuspension | | 58271 | | 01 | | Optaflu | | Injektionssuspension | | J07BB02 | | Influenza, gereinigtes Antigen | | 28.05.2009 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (A/New Caledonia/20/99 - like Reass., IVR-116) 15 µg, haemagglutininum influenzae A (H3N2) (A/California/7/2004 - like NYMC X-157) 15 µg, haemagglutininum influenzae B (Shanghai/361/2002 -like B/Jiangsu/10/2003) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | Suspension injectable | | | |
| Principe actif |
|---|
| Vaccinum Influenzae Inactivatum ex Corticis Antigeniis Praeparatum (Cellulae Mdck) 2015/2016 |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 007 | 0.5 ml | 10.05 | 19.70 | B | | Oui |
|
|
